Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

BACKGROUND: Multiple clinical trials demonstrate consistent but modest benefit of adjuvant extended endocrine therapy (EET) in HR + breast cancer patients. Predictive biomarkers to identify patients that benefit from EET are critical to balance modest reductions in risk against potential side effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sgroi, Dennis C., Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J., Brachtel, Elena, Pirrie, Sarah, Schnabel, Catherine A., Rea, Daniel, Bartlett, John M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758861/
https://www.ncbi.nlm.nih.gov/pubmed/36527133
http://dx.doi.org/10.1186/s13058-022-01589-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758861/
https://www.ncbi.nlm.nih.gov/pubmed/36527133
http://dx.doi.org/10.1186/s13058-022-01589-x

Ejemplares similares